CB1-type cannabinoid receptors in the brain mediate e¡ects of the drug cannabis. Anandamide and sn-2 arachidonylglycerol (2-AG) are putative endogenous ligands for CB1 receptors, but it is not known which cells in the brain produce these molecules. Recently, an enzyme which catalyses hydrolysis of anandamide and 2-AG, known as fatty acid amide hydrolase (FAAH), was identi¢ed in mammals. Here we have analysed the distribution of FAAH in rat brain and compared its cellular localization with CB1-type cannabinoid receptors using immunocytochemistry. High concentrations of FAAH activity were detected in the cerebellum, hippocampus and neocortex, regions of the rat brain which are enriched with cannabinoid receptors. Immunocytochemical analysis of these brain regions revealed a complementary pattern of FAAH and CB1 expression with CB1 immunoreactivity occurring in ¢bres surrounding FAAHimmunoreactive cell bodies and/or dendrites. In the cerebellum, FAAH was expressed in the cell bodies of Purkinje cells and CB1 was expressed in the axons of granule cells and basket cells, neurons which are presynaptic to Purkinje cells. The close correspondence in the distribution of FAAH and CB1 in rat brain and the complementary pattern of FAAH and CB1 expression at the cellular level provides important new evidence that FAAH may participate in cannabinoid signalling mechanisms of the brain.
INTRODUCTION
The psychoactive ingredient of cannabis, D 9 -tetrahydrocannabinol, exerts e¡ects in the brain by binding to speci¢c receptor proteins known as cannabinoid receptors (Devane et al. 1988; Pertwee 1995) . Two types of cannabinoid receptor have been characterized in mammals and are known as CB1 (Matsuda et al. 1990 ) and CB2 (Munro et al. 1993) . The CB1 cannabinoid receptor is expressed in the brain and testis, whereas the CB2 receptor is expressed by cells of the immune system (Felder & Glass 1998) . The discovery of cannabinoid receptors in the brain heralded a search for endogenous ligands and to date two candidate molecules have been identi¢ed. The ¢rst putative endocannabinoid to be identi¢ed was arachidonylethanolamide (anandamide) which was isolated from porcine brain (Devane et al. 1992) . More recently, another arachidonic acid derivative, sn-2 arachidonylglycerol (2-AG), has been identi¢ed as a possible ligand for brain cannabinoid receptors (Sugiura et al. 1995; Stella et al. 1997) .
At present little is known about the mechanisms of anandamide and 2-AG biosynthesis in neurons although various models have been proposed (Cadas et al. 1996 (Cadas et al. , 1997 Deutsch & Chin 1993; Devane & Axelrod 1994; Di Marzo et al. 1994; Felder & Glass 1998) . Assessment of anandamide and 2-AG as potential ligands for CB1 receptors in the brain will be facilitated when enzymes involved in their synthesis have been characterized. Progress has been made, however, in the characterization of an enzyme that hydrolyses anandamide and 2-AG. Anandamide amidohydrolase activity was detected in rat brain tissue soon after the discovery of anandamide (Deutsch & Chin 1993) , but molecular characterization of this enzyme was accomplished via an independent line of research. Cravatt et al. (1996) isolated an enzyme from rat liver which hydrolyses a sleep-inducing fatty acid amide (oleamide) present in the cerebrospinal £uid of sleep-deprived cats (Cravatt et al. 1995) . Characterization of the cloned`oleamide hydrolase' revealed that it is a membrane protein of ca. 63 kDa which also displays`anandamide hydrolase' activity (Cravatt et al. 1996) . The new enzyme was therefore named fatty acid amide hydrolase (FAAH) in recognition of its ability to catalyse hydrolysis of two bioactive fatty acid amides, oleamide and anandamide.
The discovery of FAAH represents an important breakthrough in cannabinoid research because it provides new strategies for assessing anandamide as a potential ligand for cannabinoid receptors. Moreover, recently it has been shown that FAAH also catalyses hydrolysis of 2-AG, the second putative endogenous cannabinoid receptor ligand (Goparaju et al. 1998 ). It appears therefore that FAAH may represent an important component of cannabinoid signalling mechanisms in the brain. In this paper we have addressed this issue by analysing the distribution of FAAH in the rat brain and comparing its expression pattern with CB1-type cannabinoid receptors at the cellular level.
MATERIALS AND METHODS
(a) FAAH enzyme activity assay Male Sprague-Dawley rats were sacri¢ced by decapitation. Brains were removed immediately, dissected into regions and placed in ice-cold phosphate-bu¡ered saline (PBS). Brain regions were homogenized in 1mM NaHCO 3 and assayed for FAAH activity as follows: 4 ml of 14 C-oleamide (¢nal concentration 100 mM, 50 mCi mmol
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) was incubated at 37 8C for 1h with 40 ml of protein (50 mg) and 156 ml of 125 mM Tris-HCl, pH 9.0. The reaction mixture was then partitioned between ethyl acetate (1ml) and 0.07 M HCl (0.6 ml). The ethyl acetate layer was concentrated under a stream of N 2 , and the remaining residue was resuspended in 15 ml of ethanol. Products were separated by thin-layer chromatography (60% ethyl acetate in hexanes), eluted from silica with scintillation £uid and quanti¢ed by scintillation counting. Each brain region was assayed in triplicate and mean activities with standard deviations were calculated. Furthermore, the experiment was repeated three times using brain tissue from di¡erent individuals, and a representative set of results from one of these experiments is illustrated in ¢gure 1.
(b) Western blot analysis
Fifty micrograms of protein from homogenized whole rat brain and brain regions were run on a 10% polyacrylamide Trisglycine gel. The gel was transferred to nitro-cellulose and probed with a 1:500 dilution of a¤nity-puri¢ed anti-FAAH rabbit polyclonal antibodies raised against a FAAH-GST fusion protein. The FAAH-GST fusion protein was generated by standard molecular biology procedures (Pharmacia) and included amino acids 385 79 of the rat FAAH protein. A¤nity puri¢cation of anti-FAAH rabbit antibodies was conducted ¢rst by depleting rabbit antiserum of GST-cross-reactive antibodies and then isolating from this serum the FAAH-GST-reactive antibodies.
(c) Immunocytochemistry
A CB1 antiserum was generated by immunizing rabbits with a conjugate of thyroglobulin and a peptide comprising the C-terminal 13 amino acids of the rat CB1 receptor (KYTMSVSTDTSAEAL). An N-terminal lysine residue was incorporated into the peptide sequence to provide a reactive site for coupling to a carrier protein (thyroglobulin) by using glutaraldehyde. A tyrosine residue was also incorporated so that radioimmunoassay could be employed to monitor antibody production in rabbits using a 125 I-labelled peptide tracer. Male adult Wistar rats were asphyxiated with CO 2 and perfused through the heart with 50 ml of 4% formaldehyde in PBS. The brains were removed, post-¢xed in Bouin's ¢xative and embedded in para¤n wax for sectioning (10 mm). Dewaxed sections were blocked with 3% normal goat serum/PBS +0.2% Triton X-100 (PBST) and then incubated with FAAH a¤nity-puri¢ed antibodies or CB1 antiserum diluted 1:50 and 1:1000 in PBST, respectively. Bound antibodies were revealed using the ABC peroxidase method (Vector Labs). The speci¢city of CB1 staining was established by performing pre-absorption experiments using the CB1-C-terminal peptide antigen (20 mM).
RESULTS AND DISCUSSION
FAAH enzyme activity was found to be concentrated in the hippocampus, neocortex, cerebellum and olfactory bulb (¢gure 1), regions of the rat brain which are also enriched with cannabinoid receptors (Herkenham et al. 1991) . Lower levels of FAAH activity were detected in other brain regions analysed (¢gure 1). To establish whether FAAH activity correlated with FAAH protein distribution in the rat brain we applied Western blotting methods using a¤nity-puri¢ed rabbit polyclonal antibodies to an FAAH-GST fusion protein. Fifty micrograms of protein from each brain region were analysed, providing a semi-quantitative method for FAAH protein measurement (¢gure 2). The FAAH protein of ca. 63 kDa was most abundant in the hippocampus and neocortex, with lower levels of FAAH being detected in each of the other brain regions examined. These results generally matched well with measurements of FAAH activity in brain regions and are consistent with the distribution of FAAH mRNA in the rat brain (Thomas et al. 1997) .
To identify which cells in the rat brain express FAAH we used immunocytochemical methods with the same FAAH antibodies that were used for Western blot analysis. FAAH immunoreactivity occurred in a distinct population of neurons in the brain but was not evident in glial cells. FAAH immunoreactive neurons were detected most predominantly in the cerebellum, hippocampus and neocortex (¢gure 3). FAAH-immunoreactive neurons were also observed in other regions of the brain (e.g. in the olfactory bulb; not shown) but not as clearly and strongly as in the cerebellum, hippocampus and neocortex. FAAH immunoreactivity was localized in the cytoplasmic compartment of the cell body and dendrites of 2082 M. Egertova¨and others Localization of FAAH and CB1 in rat brain Proc. R. Soc. Lond. B (1998) Figure 1 . FAAH activity in homogenates (50 mg of protein) of whole rat brain compared with regions of the rat brain. WB, whole brain; HC, hippocampus; CX, neocortex; CB, cerebellum; OB, olfactory bulb; ST, striatum; TH, thalamus; BS, brain stem; HT, hypothalamus. Mean values from assays performed in triplicate with standard deviation error bars are shown. Similar ¢ndings were reported while this paper was in preparation (Thomas et al. 1997). identi¢ed neurons in each brain region, including cerebellar Purkinje cells (¢gure 3a), hippocampal pyramidal cells (¢gure 3b) and neocortical pyramidal cells (¢gure 3c).
To evaluate the involvement of FAAH in cannabinoid signalling in the rat brain, we compared the anatomical distribution of FAAH with the CB1-type cannabinoid receptor at the cellular level. Antibodies to the C-terminal 13 amino acids of the rat CB1 protein were developed and used to map the distribution of cannabinoid receptors in the rat brain using immunocytochemistry. The gross distribution of CB1 immunoreactivity in the rat brain matched with previous descriptions based on cannabinoid receptor autoradiography (Herkenham et al. 1991) . Moreover, Western blot analysis of rat brain homogenates using our CB1-C-terminal antisera (data not shown) revealed staining of a band similar in molecular mass to the 52.8 kDa protein predicted by Matsuda et al. (1990) from the cDNA sequence encoding the rat CB1 receptor. Also, while this paper was in preparation, Tsou et al. (1998) reported the distribution of CB1 in the rat brain as revealed using antibodies to the N-terminal region of the CB1 receptor. The pattern of staining revealed by N-terminal antibodies appears to be generally very similar to our ¢ndings using C-terminal antibodies. However, a striking novel observation of the present analysis was the absence of CB1-immunoreactivity in neuronal cell bodies. These di¡erences in the pattern of staining observed with C-terminal and N-terminal antibodies are intriguing but it is not yet clear why such di¡erences are observed. One possibility, however, is that whilst located in neuronal cell bodies the CB1 receptor is not immunoreactive with our C-terminal antibodies due to phosphorylation of serine and/or threonine residues in the C-terminal tail. Further work is required to investigate these potentially functionally important observations. We focused our analysis of the cellular distribution of CB1 expression on the three regions of the brain in which FAAH-immunoreactive neurons were most abundant; the cerebellum, the hippocampus and the neocortex. Importantly, in all three regions, CB1 immunoreactivity was detected in nerve ¢bres located around the cell bodies and/or dendrites of neurons in which FAAH immunoreactivity was detected. The clearest example of this was seen in the cerebellum where identi¢cation of stained neurons is relatively easy (Palay & Chan-Palay 1974) .
Purkinje cells of the cerebellum exhibited FAAH immunoreactivity in their cell body and dendrites (¢gure 3a) but were completely devoid of CB1-immunoreactivity (¢gure 4a). Surrounding the dendrites of Purkinje cells, however, there was CB1 immunoreactivity in ¢bres throughout the molecular layer of the cerebellum (¢gure 4a). This pattern of staining is consistent with expression of CB1 receptors on the axons of granule cells which form a network of parallel ¢bres in the molecular layer (Palay & Chan-Palay 1974) . Moreover, this interpretation is supported by previous studies showing CB1 mRNA expression in granule cell somata (Matsuda et al. 1993) . Granule cell axons are presynaptic to Purkinje cell dendrites (Palay & Chan-Palay 1974) , and so in the cerebellum it appears that CB1-receptors are expressed in the axons of neurons (granule cells) that are presynaptic to neurons expressing FAAH (Purkinje cells). Another cerebellar cell type which is presynaptic to Purkinje cells are basket cells whose cell bodies are located in the molecular layer of the cerebellum with axons that make synaptic contact with the cell bodies of several Purkinje cells (Palay & Chan-Palay 1974) . Basket cells are unique in forming a`basket' of ¢bres around the cell bodies of Purkinje cells which makes their identi¢cation relatively easy. Analysis of CB1 immunoreactivity in the cerebellum clearly revealed stained structures around the base of Purkinje cells bodies (¢gure 4a) which match exactly with previous descriptions of basket cell axon terminals (Palay & Chan-Palay 1974) . Moreover, as with granule cells, previous in situ hybridization studies have shown CB1 mRNA expression in the somata of basket cells (Matsuda et al. 1993) . Colocalization of FAAH with CB1 was not observed in any part of the cerebellum; Purkinje cell bodies and dendrites did not exhibit CB1 immunoreactivity (¢gure 4a), and likewise granule cell axons and basket cell axons were void of FAAH immunoreactivity (¢gure 3a). These data indicate a complementary pattern of FAAH and CB1 expression, with FAAH being expressed in cell bodies and dendrites that are postsynaptic to CB1-expressing axon terminals.
A similar complementary localization of CB1 and FAAH appears to exist in the hippocampus and neocortex, although here the identi¢cation of individual neuronal types exhibiting CB1-immunoreactivity is more di¤cult than in the cerebellum. Pyramidal cells of both the neocortex and hippocampus were FAAH-immunoreactive (¢gure 3b,c) but were clearly void of CB1 immunoreactivity (¢gure 4b,c). However, surrounding the cell bodies of pyramidal cells in the hippocampus and neocortex was a network of beaded CB1-immunoreactive ¢bres (¢gure 4b,c). Although we are unable to identify the neurons which express CB1 immunoreactivity in the hippocampus and cortex, the pattern of pericellular stained ¢bres is not inconsistent with expression of CB1 in axons of neurons that are presynaptic to pyramidal cells. Our results indicate that there is a complementary pattern of FAAH and CB1 expression in the cerebellum, hippocampus and neocortex with CB1 immunoreactivity occurring in nerve ¢bres that surround the cell bodies and/or dendrites of neurons expressing FAAH. The striking correspondence in the distribution of FAAH and CB1 in these three major regions of the brain provides important new evidence that FAAH participates in cannabinoid signalling mechanisms of the brain. Moreover, if, as the data indicate, FAAH is expressed in neurons that are postsynaptic to CB1-expressing axons, this provides a new perspective on cannabinoid signalling. It suggests that the endocannabinoids anandamide and 2-AG may be inactivated by FAAH in neurons that are postsynaptic to the CB1-expressing neurons where these molecules are presumed to exert e¡ects. At present it is not known which neurons in the brain synthesize anandamide and 2-AG, and for this we must await the characterization of endocannabinoid synthases. One possibility, however, is that endocannabinoids are synthesized by neurons that are postsynaptic to CB1-expressing axon terminals. In this model, endocannabinoids could function as synaptic retrograde messenger molecules which modulate release of classical neurotransmitters by presynaptic axon terminals. This model is consistent with observed inhibitory e¡ects of anandamide and other cannabinoids on synaptic transmission in the nervous system (Cadogan et al. 1997; Collins et al. 1995; Ishac et al. 1996; Schlicker et al. 1997; Terranova et al. 1995) .
